BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 19136636)

  • 1. 3D structure of the C3bB complex provides insights into the activation and regulation of the complement alternative pathway convertase.
    Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
    Proc Natl Acad Sci U S A; 2009 Jan; 106(3):882-7. PubMed ID: 19136636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coexistence of closed and open conformations of complement factor B in the alternative pathway C3bB(Mg2+) proconvertase.
    Torreira E; Tortajada A; Montes T; Rodríguez de Córdoba S; Llorca O
    J Immunol; 2009 Dec; 183(11):7347-51. PubMed ID: 19890040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
    Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
    J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structures of C3b in complex with factors B and D give insight into complement convertase formation.
    Forneris F; Ricklin D; Wu J; Tzekou A; Wallace RS; Lambris JD; Gros P
    Science; 2010 Dec; 330(6012):1816-20. PubMed ID: 21205667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decay-accelerating factor must bind both components of the complement alternative pathway C3 convertase to mediate efficient decay.
    Harris CL; Pettigrew DM; Lea SM; Morgan BP
    J Immunol; 2007 Jan; 178(1):352-9. PubMed ID: 17182573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural analysis of engineered Bb fragment of complement factor B: insights into the activation mechanism of the alternative pathway C3-convertase.
    Ponnuraj K; Xu Y; Macon K; Moore D; Volanakis JE; Narayana SV
    Mol Cell; 2004 Apr; 14(1):17-28. PubMed ID: 15068800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insights Into Enhanced Complement Activation by Structures of Properdin and Its Complex With the C-Terminal Domain of C3b.
    van den Bos RM; Pearce NM; Granneman J; Brondijk THC; Gros P
    Front Immunol; 2019; 10():2097. PubMed ID: 31552043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
    Pryzdial EL; Isenman DE
    J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B.
    Hinshelwood J; Spencer DI; Edwards YJ; Perkins SJ
    J Mol Biol; 1999 Nov; 294(2):587-99. PubMed ID: 10610782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into complement convertase formation based on the structure of the factor B-cobra venom factor complex.
    Janssen BJ; Gomes L; Koning RI; Svergun DI; Koster AJ; Fritzinger DC; Vogel CW; Gros P
    EMBO J; 2009 Aug; 28(16):2469-78. PubMed ID: 19574954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bispecific inhibitor of complement and coagulation blocks activation in complementopathy models via a novel mechanism.
    Andersen JF; Lei H; Strayer EC; Kanai T; Pham V; Pan XZ; Alvarenga PH; Gerber GF; Asojo OA; Francischetti IMB; Brodsky RA; Valenzuela JG; Ribeiro JMC
    Blood; 2023 Jun; 141(25):3109-3121. PubMed ID: 36947859
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular dissection of interactions between components of the alternative pathway of complement and decay accelerating factor (CD55).
    Harris CL; Abbott RJ; Smith RA; Morgan BP; Lea SM
    J Biol Chem; 2005 Jan; 280(4):2569-78. PubMed ID: 15536079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.
    Katschke KJ; Stawicki S; Yin J; Steffek M; Xi H; Sturgeon L; Hass PE; Loyet KM; Deforge L; Wu Y; van Lookeren Campagne M; Wiesmann C
    J Biol Chem; 2009 Apr; 284(16):10473-9. PubMed ID: 19196712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.
    Hourcade DE; Mitchell L; Kuttner-Kondo LA; Atkinson JP; Medof ME
    J Biol Chem; 2002 Jan; 277(2):1107-12. PubMed ID: 11694537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of the zymogenicity and the substrate-induced activity enhancement of complement factor D.
    Dani R; Oroszlán G; Martinusz R; Farkas B; Dobos B; Vadas E; Závodszky P; Gál P; Dobó J
    Front Immunol; 2023; 14():1197023. PubMed ID: 37283768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The tick-over theory revisited: formation and regulation of the soluble alternative complement C3 convertase (C3(H2O)Bb).
    Bexborn F; Andersson PO; Chen H; Nilsson B; Ekdahl KN
    Mol Immunol; 2008 Apr; 45(8):2370-9. PubMed ID: 18096230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor.
    Rooijakkers SH; Wu J; Ruyken M; van Domselaar R; Planken KL; Tzekou A; Ricklin D; Lambris JD; Janssen BJ; van Strijp JA; Gros P
    Nat Immunol; 2009 Jul; 10(7):721-7. PubMed ID: 19503103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
    Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
    Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational changes during the assembly of factor B from its domains by (1)H NMR spectroscopy and molecular modelling: their relevance to the regulation of factor B activity.
    Hinshelwood J; Perkins SJ
    J Mol Biol; 2000 Sep; 301(5):1267-85. PubMed ID: 10966820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease models.
    Subías M; Tortajada A; Gastoldi S; Galbusera M; López-Perrote A; Lopez Lde J; González-Fernández FA; Villegas-Martínez A; Dominguez M; Llorca O; Noris M; Morgan BP; Rodríguez de Córdoba S
    J Immunol; 2014 Dec; 193(11):5567-75. PubMed ID: 25355917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.